| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 8099.8 | 7546.4 | 8572.1 |
| Other income | 354.7 | 475.4 | 290.3 |
| Total income | 8454.5 | 8021.8 | 8862.4 |
| Profit before exceptional items & tax | 553.3 | 199.7 | 1905.0 |
| Profit before tax | 553.3 | 199.7 | 1905.0 |
| Net profit | 435.6 | 221.3 | 1409.9 |
| Operating margin | 6.5% | 2.5% | 21.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -69.10% |
|---|---|
| Net profit, quarter on quarter | +96.80% |
| Revenue, year on year | -5.50% |
| Operating profit, year on year | -92.80% |
| Operating profit, quarter on quarter | +131.80% |
BSE results filing, NSE: DRREDDY. Figures extracted from the filing.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,201.00
- Market cap
- ₹1,00,245 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 31.1×Sector 50.4×
- Promoter holding
- 26.64%+0.01% QoQ
- FII holding
- 20.67%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Board Meeting Date
Dr. Reddy’s Laboratories will hold a board meeting on October 23, 2026, to approve the standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Reddy's Laboratories Partnership
Dr. Reddy's signed an exclusive distribution agreement with Takeda for Qdenga dengue vaccine in India's private market. No upfront consideration stated; availability expected H1 2027.
Dr. Reddy's Laboratories Price Movement Clarification
Dr. Reddy's confirmed a news report regarding a voluntary licensing agreement with Gilead Sciences for an HIV prevention drug, noting it is not material.
Dr. Reddy's Laboratories Business Update
Dr. Reddy's Laboratories received two observations from the USFDA following a records assessment of its API manufacturing facility in Jiutepec, Mexico.
Dr. Reddy's Laboratories Employee Stock Options
Dr. Reddy's Laboratories allotted 375 equity shares to employees upon the exercise of stock options under its ESOP scheme.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Q1FY27 revenue fell 5.6% YoY to ₹8,071 Cr due to lower Lenalidomide sales. EBITDA margin at 12.5% (15.4% ex-one-offs) was hit by semaglutide API issues and Middle East conflict costs.